Recent Updates
Recently added Catalysts
VBIO Positive Sentiment

Valion Bio Reports Completion of 200-Liter Entolimod Production Run; Material Supplying Ongoing AFRRI Study

Key Takeaway: Valion Bio reported the completion of a 200-liter Entolimod production run, achieving 27% higher productivity than historical data. The drug substance met all quality criteria and is supplying an ongoing study funded by NIAID. This production run marks a significant scale-up in manufacturing for the company’s lead candidate, Entolimod.

Market Sentiment Analysis

POSITIVE FACTORS

  • 200-liter run achieved 27% higher productivity
  • Drug substance met all predefined acceptance criteria
  • Material supports ongoing study funded by NIAID
  • Entolimod has received Fast Track and Orphan Drug designations

Full Press Release Details

The first and only All-in-one subscription platform offering all of your PR Distribution and Media Outreach Tools in one single solution. Monthly & Annual Subscriptions.
Find & create journalist lists with the most up to date database in the industry.
Personalize and customize your pitch for maximum engagement.
Discover your brand, industry, and competitor mentions.
Now you can track every mention, every conversation, and every shift in sentiment — all from the platform you're already using.
Turn your PR data into actionable intelligence with comprehensive reporting and analytics on every campaign.
Catch issues before our editors do. ACCESS Verified gives you a real-time first pass on your press release so you can submit with confidence — every time.
The first and only All-in-one subscription platform that offers you the ability to manage all of your IR communications needs from a single source. Explore our IR subscriptions
Explore how you can upgrade your IR Site today.
Ensure your IR Site is accessible for your entire audience.
Experience seamless calls with our dedicated team of domestic operators.
Easily send your releases out with quick turnarounds and no extra fees.
Host your day knowing you've got the most experienced webcast team in the industry.
Provide a secure and confidential reporting channel to protect your organization and employees.
Streamline your PR & IR needs with one platform.
Easily schedule and manage your investor meetings with our comprehensive and easy to use software.
Our PR and IR tools are designed to meet all necessary regulatory requirements, giving you the confidence to communicate effectively and compliantly. Streamline your communications needs today with our one-stop shop offering.
Whether a startup or established brand, we deliver the support, targeted distribution, media outreach, and flexible pricing & payment options needed to amplify your story with confidence.
We simplify the process of delivering success for both you and your clients. We understand the importance of getting it right, equipping you with seamless billing, flexible plans and payment structures, and clear reporting and analytics to ensure every campaign runs smoothly and achieves measurable results.
We understand the need to manage high volume of press release distribution efficiently. That's why we offer a dedicated API designed specifically for our legal customers, delivering a streamlined, simple process that ensures value and ease at every step.
We understand the importance of cost efficiency for high-volume partners, which is why we offer bulk discounts tailored to meet your needs while maximizing value.
Designed for brands that need help consistently fueling their content strategy and calendar with optimized press releases, blogs, and more…
Tailored for brands with a solid content strategy seeking support for effectively reaching and engaging the media.
Made for brands that need more comprehensive support building and managing their content strategy, media outreach and engagement plan.
Personalized support to optimize your platform, including tailored journalist list creation, pitch guidance, and monitoring setup.
Continual support and management including ongoing list creation, pitch creation and modifications, monitoring adjustments, and additional reporting and analytics review.
Press Release creation and optimization for SEO and audience engagement
Back to the Newsroom Valion Bio Reports Completion of 200-Liter Entolimod Production Run; Material Supplying Ongoing AFRRI Study Tuesday, 17 November 2026 08:05 AM
Production run achieved approximately 27% higher productivity compared with historical manufacturing data while meeting all predefined drug substance acceptance criteria
SAN ANTONIO, TX / ACCESS Newswire / November 17, 2026 / Valion Bio, Inc. (NASDAQ:VBIO) ("Valion" or the "Company"), a clinical-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation, today reported that its wholly owned subsidiary, Velocity Bioworks, completed a 200-liter non-GMP production run of Entolimod at its San Antonio, Texas facility. The run, conducted from May through June 2026, achieved approximately 27% higher productivity compared with historical manufacturing data, and the resulting drug substance met all predefined acceptance criteria for the quality attributes assessed.
Drug product from the run was filled in June and is supplying the Company's ongoing Entolimod study, a study fully funded by the National Institute of Allergy and Infectious Diseases ("NIAID")/Radiation and Nuclear Countermeasures Program (RNCP) under an Interagency Agreement with the Uniformed Services University ("USU")/Armed Forces Radiobiology Research Institute ("AFRRI").
The 200-liter run followed a 50-liter production run completed in January 2026. The 200-liter scale is widely recognized as the pivotal bridge between laboratory innovation and clinical reality in biopharmaceutical manufacturing. This scale represents the transition from benchtop process development to CGMP clinical trial material production. 1,2
"This run increased our production scale fourfold while also improving productivity. The resulting drug substance met all of our acceptance criteria, with the process yielding more drug substance per liter of fermentation volume," said Dean Zikria, Interim Chief Executive Officer of Valion. "The material is now supporting our ongoing study with AFRRI. We're reporting these results as part of our commitment to keeping shareholders informed of progress on our lead program."
Entolimod is being developed as a potential medical countermeasure for Acute Radiation Syndrome under the FDA's Animal Rule and has received Fast Track and Orphan Drug designations. The Company expects to apply what it learned from this run as it plans future CGMP manufacturing for Entolimod and continues to evaluate strategic alternatives for Velocity Bioworks.
1 DDN, The ultimate guide to bioprocessing scale-up and Pharma 4.0, https://www.drugdiscoverynews.com/the-ultimate-guide-to-bioprocessing-scale-up-and-pharma-4-0-17209
2 BioProcess International, Lessons in Bioreactor Scale-Up: Part 1 - Exploring Introductory Principles, https://www.bioprocessintl.com/bioreactors/lessons-in-bioreactor-scale-up-part-1-mdash-exploring-introductory-principles
Valion Bio, Inc. (NASDAQ:VBIO) is developing biologics that activate innate immune pathways for cytoprotection and modulate immune responses in conditions driven by radiation, disease and immune dysregulation.
The Company's lead candidate, Entolimod, is being developed as a potential medical countermeasure for Acute Radiation Syndrome ("ARS") and has been evaluated in animal models under the U.S. Food and Drug Administration's ("FDA") Animal Rule, which allows the Agency to approve new drugs and biological products based on animal efficacy studies when human clinical trials are not ethical or feasible, such as in the case of acute radiation exposure. Entolimod is a novel Toll-like Receptor 5 agonist designed to activate NF-κB signaling pathways associated with cellular protection, tissue recovery and immune response. The product candidate has received Fast Track and Orphan Drug designations from the FDA. Valion holds an exclusive, worldwide license from Statera Biopharma to develop and commercialize Entolimod for ARS, radiation-induced neutropenia, and other indications.
Valion is also advancing Entolasta, a next-generation TLR5 agonist designed for potential use in broader therapeutic applications, including oncology supportive care. The Company's pipeline includes potential programs in neutropenia and immune dysfunction.
Valion's wholly owned subsidiary, Velocity Bioworks, is a biologics contract development and manufacturing organization with mammalian and microbial capabilities, focused on increasing manufacturing control, reducing costs, accelerating development timelines and strengthening domestic supply-chain security.
For more information, visit www.valionbio.com .
This press release may contain "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Valion's current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Forward-looking statements in this press release include, among others, statements regarding: the development and regulatory advancement of Entolimod under the FDA Animal Rule; the timing and outcome of regulatory or government interactions; the Company's ability to advance toward 200-liter CGMP manufacturing; the interest of governments or other entities in stockpiling nuclear exposure countermeasures or other biologic drugs; the initiation, design, timing and outcome of investigator-sponsored studies in neutropenia; the development and potential applications of Entolasta; the ability of the Company to expand the TLR5 platform into oncology supportive care or other indications; and the Company's ability to obtain additional capital and the continued listing of the Company's common stock on the Nasdaq Capital Market. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Valion's actual results to differ from those contained in the forward-looking statements, see Valion's filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 30, 2026, under the heading "Risk Factors"; as well as the Company's subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and Valion undertakes no duty to update such information except as required by applicable law.

Frequently Asked Questions

What did Valion Bio achieve with the 200-liter run?

The run achieved 27% higher productivity compared to historical data.

What is Entolimod being developed for?

Entolimod is a potential countermeasure for Acute Radiation Syndrome.

Who funded the ongoing study for Entolimod?

The study is fully funded by the NIAID under an Interagency Agreement.

What designations has Entolimod received?

Entolimod has received Fast Track and Orphan Drug designations from the FDA.

Last updated: Nov 17, 2026